Acciones Coeptis Therapeutics, Inc. OTC Markets
Acciones
COEP
US19207C1045
Farmacéuticos
Ventas 2024 * | - | Ventas 2025 * | - | Capitalización | 11,62 M 10,83 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | -26 M -24,24 M | Resultado Neto 2025 * | -35 M -32,63 M | VE / Ventas 2024 * | - |
Posición de caja neta 2024 * | - 0 | Posición de caja neta 2025 * | - 0 | VE / Ventas 2025 * | - |
P/E ratio 2024 * |
-0,42
x | P/E ratio 2025 * |
-0,37
x | Empleados | 6 |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 67,46 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28/10/22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17/05/23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28/10/22 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Director/Board Member | 62 | 28/10/22 | |
Director/Board Member | 55 | 28/10/22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28/10/22 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+24,17 % | 562 mil M | |
-6,33 % | 358 mil M | |
+19,90 % | 322 mil M | |
+7,95 % | 297 mil M | |
+13,45 % | 219 mil M | |
+6,04 % | 199 mil M | |
-10,51 % | 196 mil M | |
-12,26 % | 149 mil M | |
-6,47 % | 146 mil M |